William Daly - Senior Vice President- Business Development
William Daly joins us from Halozyme Therapeutics, where he was the Head of Business Development and Alliance Management. Prior to his joining the company, Halozyme had not completed a new partnership in more than four years – Bill was successful in completing three new partnerships in less than a year. He also oversaw Halozyme’s alliances with Roche (for the development of subcutaneous formulations of Herceptin, MabThera (Rituxan) and Actemra) and Baxter BioScience (for HyQvia).
Prior to Halozyme, Bill was Senior Vice President – Business Development at Cougar Biotechnology. At Cougar, Bill was responsible for the acquisition of Cougar by Johnson & Johnson for $1 billion. Following the acquisition, Bill co-led the integration of Cougar and J&J and was also Site Head of the Los Angeles facility, which was conducting two phase 3 trials of the prostate cancer drug, abiraterone acetate. Both of these trials were halted early due to successful interim survival analyses in which all primary and secondary endpoints were achieved with statistical significance. Abiraterone acetate has since been successfully launched in the US and Europe under the brand name Zytiga.
Prior to joining Cougar, Bill held a number of business development and senior executive positions over the past ten years at Allergan, Chiron and Novartis as well as a number of start-up biotechnology companies. Before moving into industry, Bill was an investment banker for nine years, most recently served as a Managing Director for Prudential Vector Healthcare Group. He focused on healthcare (primarily pharma and biotech) companies and completed transactions totaling more than $5 billion during his tenure as an investment banker.
Prior to becoming an investment banker, Bill practiced corporate and securities law for ten years. He worked at a major East Coast law firm and was a partner in a boutique securities firm in Los Angeles.
Bill graduated from UC Berkeley with a degree in biochemistry and earned his law degree and his MBA from UCLA.